Alternative matrices for cocaine, heroin, and methadone in utero drug exposure detection

Therapeutic Drug Monitoring

Volumn 35, Issue 4, 2013, Pages 502-509

  Concheiro, Marta ^a,b   González Colmenero, Eva ^c   Lendoiro, Elena ^a   Concheiro Guisán, Ana ^c   De Castro, Ana ^a,d   Cruz Landeira, Angelines ^a   López Rivadulla, Manuel ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^d Cienytech SL   (Spain)

Author keywords

drugs of abuse; hair; meconium; placenta; umbilical cord

Indexed keywords

2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; AMPHETAMINE DERIVATIVE; BENZOYLECGONINE; COCAINE; CODEINE; DIAMORPHINE; ECGONINE METHYL ESTER; METHADONE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 ACETATE; OPIATE;

ARTICLE; COMPARATIVE STUDY; DRUG DISPOSITION; FEMALE; HAIR; HAIR ANALYSIS; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MECONIUM; NEWBORN; PLACENTA; PRENATAL EXPOSURE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; UMBILICAL CORD;

CHROMATOGRAPHY, LIQUID; COCAINE; DRUG MONITORING; FEMALE; HAIR; HEROIN; HUMANS; MATERNAL-FETAL EXCHANGE; MECONIUM; METHADONE; PLACENTA; PREGNANCY; SUBSTANCE ABUSE DETECTION; TANDEM MASS SPECTROMETRY; UMBILICAL CORD; UTERUS;

EID: 84880570626     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31828a6148     Document Type: Article

References (32)

1. White SM. The effect of controlled drugs on the unborn child and fetus. J Clin Forensic Med. 2001;8:129-139.
2. Sithisarn T, Granger DT, Bada HS. Consequences of prenatal substance use. Int J Adolesc Med Health. 2012;24:105-112.
3. Wilcox AJ, Weinberg CR, Baird DD. Risk factors for early pregnancy loss. Epidemiology. 1990;1:382-385.
4. 2011 National Survey on Drug Use and Health. Available at: http://www. samhsa.gov/data/NSDUH/2k11Results/NSDUHresults2011.pdf. Accessed November 8, 2012.
5. Garcia-Algar O, Vall Combelles O, Puig Sola C, et al. Prenatal exposure to drugs of abuse using meconium analysis in a low socioeconomic population in Barcelona [in Spanish]. An Pediatr (Barc). 2009;70: 151-158.
6. Ostrea EM Jr, Knapp DK, Tannenbaum L, et al. Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis. J Pediatr. 2001;138:344-348.
7. Friguls B, Joya X, Garica-Serra J, et al. Assessment of exposure to drugs of abuse during pregnancy by hair analysis in a Mediterranean island. Addiction. 2012;107:1471-1479.
8. Gray T, Huestis M. Bioanalytical procedures for monitoring in utero drug exposure. Anal Bioanal Chem. 2007;388:1455-1465.
9. Lozano J, Garcia-Algar O, Vall O, et al. Biological matrices for the evaluation of in utero exposure to drugs of abuse. Ther Drug Monit. 2007;29:711-734.
10. Gallardo E, Queiroz JA. The role of alternative specimens in toxicological analysis. Biomed Chromatogr. 2008;22:795-821.
11. Pragst F, Balikova MA. State of the art in hair analysis for detection of drug and alcohol abuse. Clin Chim Acta. 2006;370:17-49.
12. Casanova OQ, Lombardero N, Behnke M, et al. Detection of cocaine exposure in the neonate. Analyses of urine, meconium, and amniotic fluid from mothers and infants exposed to cocaine. Arch Pathol Lab Med. 1994;118:988-993.
13. Kacinko SL, Jones HE, Johnson RE, et al. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther. 2008:84: 604-612.
14. Pichini S, Altieri I, Zuccaro P, et al. Drug monitoring in nonconventional biological fluids and matrices. Clin Pharmacokinet. 1996;30:211-228.
15. de Castro A, Jones HE, Johnson RE, et al. Maternal methadone dose, placental methadone concentrations, and neonatal outcomes. Clin Chem. 2011;57:449-458.
16. Concheiro M, Jones HE, Johnson RE, et al. Maternal buprenorphine dose, placenta buprenorphine, and metabolite concentrations and neonatal outcomes. Ther Drug Monit. 2010;32:206-215.
17. Falcon M, Pichini S, Joya J, et al. Maternal hair testing for the assessment of fetal exposure to drug of abuse during early pregnancy: comparison with testing in placental and fetal remains. Forensic Sci Int. 2012;218: 92-96.
18. Garcia-Algar O, Lopez-Vilchez MA, Martin I, et al. Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis. Clin Toxicol (Phila). 2007;45:295-298.
19. Martin I, Lopez-Vilchez MA, Mur A, et al. Neonatal withdrawal syndrome after chronic maternal drinking of mate. Ther Drug Monit. 2007; 29:127-129.
20. Garcia-Algar O, Vall O, Alameda F, et al. Prenatal exposure to arecoline (areca nut alkaloid) and birth outcomes. Arch Dis Child Fetal Neonatal Ed. 2005;90:F276-F277.
21. de Castro A, Jones HE, Johnson RE, et al. Methadone, cocaine, opiates, and metabolites disposition in umbilical cord and correlations to maternal methadone dose and neonatal outcomes. Ther Drug Monit. 2011;33:443-452.
22. Concheiro M, Jones HE, Johnson RE, et al. Umbilical cord monitoring of in utero drug exposure to buprenorphine and correlation with maternal dose and neonatal outcomes. J Anal Toxicol. 2010;34:498-505.
23. Montgomery D, Plate C, Alder SC, et al. Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium. J Perinatol. 2006; 26:11-14.
24. Moore CM, Brown S, Negrusz A, et al. Determination of cocaine and its major metabolite, benzoylecgonine, in amniotic fluid, umbilical cord blood, umbilical cord tissue, and neonatal urine: a case study. J Anal Toxicol. 1993;17:62.
25. Winecker RE, Goldberger BA, Tebbett I, et al. Detection of cocaine and its metabolites in amniotic fluid and umbilical cord tissue. J Anal Toxicol. 1997;21:97-104.
26. Lendoiro E, Quintela O, de Castro A, et al. Target screening and confirmation of 35 licit and illicit drugs and metabolites in hair by LC-MSMS. Forensic Sci Int. 2012;217:207-215.
27. Garcia-Bournisee F, Rokach B, Karaskov T, et al. Cocaine detection in maternal and neonatal hair: implications to fetal toxicology. Ther Drug Monit. 2007;29:71-76.
28. Savitz DA, Henderson L, Dole N, et al. Indicators of cocaine exposure and preterm birth. Obstet Gynecol. 2002;99:458-465.
29. Garcia-Bournisse F, Rokach B, Karaskov T, et al. Methamphetamine detection in maternal and neonatal hair: implications for fetal safety. Arch Dis Child Fetal Neonatal Ed. 2007;92:351-355.
30. Moller M, Karaskov T, Koren G. Opioid detection in maternal and neonatal hair and meconium: characterization of an at-risk population and implications to fetal toxicology. Ther Drug Monit. 2010;32:318-323.
31. Le Beau M, Montgomery MA, Brewer JD. The role of variations in growth rate and sample collection on interpreting results of segmental analysis of hair. Forensic Sci Int. 2011;210:110-116.
32. Srinivasan K, Wang PP, Eley AT, et al. Liquid chromatography-tandem mass spectrometry analysis for cocaine and its metabolites from blood, amniotic fluid, placental and fetal tissues: study of the metabolism and distribution of cocaine in pregnant rats. J Chromatogr B: Biomed Sic Appl. 2000;745:287-303. Galicia